Specific microbiome patterns and their association with breast cancer: the intestinal microbiota as a potential biomarker and therapeutic strategy
Open Access
- 18 June 2024
- journal article
- review article
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 27 (1) , 15-41
Abstract
Breast cancer (BC) is one of the most diagnosed cancers in women. Based on histological characteristics, they are classified as non-invasive, or in situ (tumors located within the milk ducts or milk lobules) and invasive. BC may develop from in situ carcinomas over time. Determining prognosis and predicting response to treatment are essential tools to manage this disease and reduce its incidence and mortality, as well as to promote personalized therapy for patients. However, over half of the cases are not associated with known risk factors. In addition, some patients develop resistance to treatment and relapse. Therefore, it is necessary to identify new biomarkers and treatment strategies that improve existing therapies. In this regard, the role of the microbiome is being researched as it could play a role in carcinogenesis and the efficacy of BC therapies. This review aims to describe specific microbiome patterns associated with BC. For this, a literature search was carried out in PubMed database using the MeSH terms “Breast Neoplasms” and “Gastrointestinal Microbiome”, including 29 publications. Most of the studies have focused on characterizing the gut or breast tissue microbiome of the patients. Likewise, studies in animal models and in vitro that investigated the impact of gut microbiota (GM) on BC treatments and the effects of the microbiome on tumor cells were included. Based on the results of the included articles, BC could be associated with an imbalance in the GM. This imbalance varied depending on molecular type, stage and grade of cancer, menopause, menarche, body mass index, and physical activity. However, a specific microbial profile could not be identified as a biomarker. On the other hand, some studies suggest that the GM may influence the efficacy of BC therapies. In addition, some microorganisms and bacterial metabolites could improve the effects of therapies or influence tumor development.Keywords
Funding Information
- Universidad de Granada
This publication has 115 references indexed in Scilit:
- Increased abundance of Sutterella spp. and Ruminococcus torques in feces of children with autism spectrum disorderMolecular Autism, 2013
- Novel dextran from Pediococcus pentosaceus CRAG3 isolated from fermented cucumber with anti-cancer propertiesInternational Journal of Biological Macromolecules, 2013
- Reduced Incidence of Prevotella and Other Fermenters in Intestinal Microflora of Autistic ChildrenPLOS ONE, 2013
- Gut metagenome in European women with normal, impaired and diabetic glucose controlNature, 2013
- The biodiversity and composition of the dominant fecal microbiota in patients with inflammatory bowel diseaseDiagnostic Microbiology and Infectious Disease, 2013
- Intestinal Inflammation Targets Cancer-Inducing Activity of the MicrobiotaScience, 2012
- Molecular characterization of mucosal adherent bacteria and associations with colorectal adenomasGut Microbes, 2010
- Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patientsProceedings of the National Academy of Sciences, 2008
- Unique features of breast cancer in TaiwanBreast Cancer Research and Treatment, 2000
- Molecular portraits of human breast tumoursNature, 2000